Online inquiry

IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ626MR)

This product GTTS-WQ626MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL9 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000590.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3578
UniProt ID P15248
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ626MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7578MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ6784MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ4399MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ3329MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ11560MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ5399MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ2615MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW